Tower Research Capital LLC TRC Boosts Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

Tower Research Capital LLC TRC raised its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 308.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,391 shares of the company's stock after acquiring an additional 46,378 shares during the quarter. Tower Research Capital LLC TRC's holdings in Vir Biotechnology were worth $451,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Artisan Partners Limited Partnership purchased a new stake in Vir Biotechnology in the 4th quarter worth $6,742,000. Dimensional Fund Advisors LP raised its stake in Vir Biotechnology by 58.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company's stock valued at $14,059,000 after purchasing an additional 703,360 shares in the last quarter. Alta Partners Management Company L.P. purchased a new stake in shares of Vir Biotechnology during the 4th quarter valued at about $3,593,000. Walleye Capital LLC lifted its stake in shares of Vir Biotechnology by 2,119.4% in the 4th quarter. Walleye Capital LLC now owns 434,460 shares of the company's stock valued at $3,189,000 after purchasing an additional 414,884 shares during the last quarter. Finally, abrdn plc bought a new stake in Vir Biotechnology in the fourth quarter worth $2,666,000. Institutional investors own 65.32% of the company's stock.

Vir Biotechnology Trading Down 1.1 %

Vir Biotechnology stock traded down $0.07 during mid-day trading on Monday, hitting $6.09. The company had a trading volume of 205,140 shares, compared to its average volume of 1,330,489. The company has a market capitalization of $840.81 million, a price-to-earnings ratio of -1.55 and a beta of 1.36. Vir Biotechnology, Inc. has a 12-month low of $4.95 and a 12-month high of $14.45. The company's fifty day moving average is $6.55 and its 200-day moving average is $8.01.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm had revenue of $12.37 million for the quarter, compared to the consensus estimate of $8.14 million. As a group, sell-side analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Barclays boosted their target price on Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. HC Wainwright reiterated a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, February 28th. Leerink Partners upped their price target on Vir Biotechnology from $18.00 to $20.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 price objective on shares of Vir Biotechnology in a research report on Thursday, February 27th. Finally, Morgan Stanley raised Vir Biotechnology from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $33.57.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, EVP Verneuil Vanina De sold 7,373 shares of the stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total transaction of $67,389.22. Following the completion of the transaction, the executive vice president now owns 79,460 shares of the company's stock, valued at $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Backer Marianne De sold 79,712 shares of the firm's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total value of $474,286.40. Following the completion of the transaction, the chief executive officer now owns 769,505 shares in the company, valued at $4,578,554.75. The trade was a 9.39 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 99,611 shares of company stock valued at $663,525. Company insiders own 15.60% of the company's stock.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).